Reata Pharmaceuticals (NASDAQ:RETA) Price Target Raised to $115.00

Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its target price raised by Stifel Nicolaus from $105.00 to $115.00 in a research report report published on Thursday, The Fly reports. A number of other research analysts have also commented on RETA. Citigroup lifted their price objective on shares of Reata Pharmaceuticals from $53.00 to $120.00 and […]

Related Keywords

Alger ,Algeria ,Stifel Nicolaus ,Andrea Loewen ,Securities Exchange Commission ,Citigroup ,Institutional Investors Weigh In On Reata Pharmaceuticals ,Analyst Recommendations For Reata Pharmaceuticals ,Reata Pharmaceuticals Inc ,Goldman Sachs Group ,Cantor Fitzgerald ,Reata Pharmaceuticals ,News Ratings For Reata Pharmaceuticals Daily ,First Light Asset Management ,Morgan Stanley ,Fred Alger Management ,Deutsche Bank ,Reata Pharmaceuticals Stock Down ,Get Rating ,Moderate Buy ,Pharmaceuticals Stock Down ,Director Shamim Ruff ,Exchange Commission ,Light Asset Management ,Alger Management ,Reata Pharmaceuticals Daily ,Nasdaq Reta ,Greta ,Medical ,Boost Price Target ,